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Few B-vitamin trials to lower homocysteine (Hcy) have reported evidence of beneﬁcial effects on
cognition in older adults with cognitive impairment or Alzheimer’s disease. This article reviews the role
of Hcy in cognitive decline. It also considers some reasons why meta-analyses have failed to ﬁnd effects
of B-vitamin treatment. Findings from the successful VITACOG trial are examined from a new perspective
of critical levels of Hcy and brain atrophy that may impact on the efﬁcacy of B-vitamin treatment. It
appears that there is a critical level of brain shrinkage, possibly mediated by elevated Hcy, which when
reached, results in cognitive decline, especially in episodic memory performance. Supplements, food
sources, and effects of folic acid fortiﬁcation are discussed in relation to B12 deﬁciency.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Risk factors for Alzheimer’s disease (AD) affecting the rate of
cognitive decline and brain shrinkage include nonmodiﬁable fac-
tors such as age, low education levels, and genetic factors, whereas
modiﬁable risk factors have also been identiﬁed. One such modi-
ﬁable risk factor is homocysteine (Hcy), an amino acid that is pro-
duced in the methylation cycle of protein metabolism. The
association between elevated plasma Hcy and cognitive impair-
ment has been well established (Budge et al., 2002; McCaddon
et al., 2001; Seshadri, 2006), although the underlying mecha-
nisms to explain the association are still being researched.1.1. The Hcy pathway
Hcy is produced via protein metabolism. The conversion of Hcy
to useful metabolites, S-adenosyl methionine and glutathione,e, University of Cape Town,
rica. Tel.: þ27 (0)21 4066538;
, L51, OMB, Groote Schuur
Town, Western Cape 7925,
Y-NC-ND license.requires vitamins B9 (methyl folate), B12 (cobalamin), and B6
(pyridoxine) as cofactors (Morris, 2012a; Refsum et al., 2006).
Hence, if the B-vitamin supply through the diet is suboptimal,
remethylation of Hcy via the enzyme methionine synthase is
reduced, and plasma levels of Hcy rise. The importance of the
remethylation process is the regeneration of the active form of
folate, tetrahydrofolate, needed for thymidine synthesis, DNA
replication, and neurogenesis. S-adenosyl methionine is a methyl
donor for the central nervous system and important to neuro-
transmitter synthesis. Vitamin B12 is also important for fatty acid
metabolism, acting as a cofactor for the enzyme methylmalonyl-
CoA mutase and also promoting neural membrane formation.
Buildup of methylmalonic acid (MMA) indicates the loss of this B12
function. Disruption of any of these pathways is likely to lead to loss
of cognitive function and contribute to neuronal atrophy. Increased
oxidative stress occurs in the brain when Hcy is elevated (Birch
et al., 2009) and may increase the permeability of blood brain
barrier. It is well known that vitamin B12 deﬁciency is a cause of
pernicious or megaloblastic anemia, peripheral neuropathy, lack of
energy, and poor memory.
Hcy levels rise with age (Nygård et al., 1998), possibly because of
poor absorption of B vitamins from the diet and other factors
includingmale sex, smoking, high blood pressure, and other clinical
conditions (Refsum et al., 2006). However, studies in AD patients
Fig. 1. Simpliﬁed model of causal links determined by Bayesian network analysis of
B-vitamin treatment and changes in homocysteine, gray matter volume, and cognitive
performance over 2 years (as described in Douaud et al., 2013).
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controls, whereas folate and B12 levels are lower (Clarke et al.,
1998).
1.2. Brain shrinkage, Hcy, and cognitive decline
Brain shrinkage because of cortical atrophy occurs with normal
aging (Fjell et al., 2009; Thambisetty et al., 2010). The rate of brain
atrophy has been shown to be a marker of cognitive decline (Fox
et al., 1999) in domains such as memory, processing speed, and
executive function (Fjell and Walhovd, 2010).
A 5-year study of people older than 60 years showed that per-
centage brain volume loss occurred at an average rate of 0.7% 0.3%
per year (Vogiatzoglou et al., 2008). However, the decrease in brain
volumewas greater among thosewith lower vitamin B12 levels and
markers of functional B12 including holo-transcobalamin at base-
line. Brain volume loss was also associated with higher plasma total
Hcy and MMA levels at baseline. For those with the lowest tertile of
baseline vitamin B12 (<308 pmol/L), there was a 6-fold increase in
the rate of brain volume loss. Elevated total Hcy is also associated
with a smaller hippocampus in community-dwelling older adults
(Williams et al., 2002). Minimal hippocampal width was shown to
decline by 0.7 mm for each 10 micromolar increment in Hcy.
The rate of brain atrophy is known to be increased with
neurodegenerative diseases such as AD. Atrophy in the medial
temporal lobes becomes detectable by brain imaging at an early
stage and is followed by increasing atrophy spreading to other re-
gions of the brain in a sequential pathway (Smith, 2002). Rates of
atrophy in those with AD can reach up to 12% per year and have
been directly associated with cognitive decline starting in the
domain of episodic memory and later involving domains of atten-
tion, executive function, processing speed, language, visuospatial
skills, and orientation.
Hcy levels have also been associated with cognitive decline. For
example, the Hordaland Homocysteine Study found that a rise in
Hcy levels over time (6 years of follow-up) predicted cognitive
decline (Nurk et al., 2005). This association has been conﬁrmed in
other studies (McCaddon et al., 2001) and reviews (Sachdev, 2005)
and shown to be age dependent (Oulhaj et al., 2010). Controversies
to these ﬁndings have been discussed by Morris (2012a).
2. Interventions with B vitamins
Randomized controlled trials (RCTs) to delay cognitive decline
with B vitamins have been performed in participants with and
without cognitive impairment and AD. Most reviews of these RCTs
have shown little support for the efﬁcacy of interventions by meta-
analysis of data (Clarke and Bennett, 2008; Malouf and Grimley
Evans, 2008), even when selecting only studies >6 months long,
those in countries without folic acid fortiﬁcation, those that
included folic acid, and those with >100 participants (Ford and
Almeida, 2012). Longer intervention, larger sample size, and the
suggested efﬁcacy of folic acid supplementation should have
improved the likelihood of showing treatment effects of B vitamins.
However, there were other issues that may have limited the ﬁnd-
ings. These included analyses of studies with normal participants
combined with those with hypertension, cardiovascular disease,
low baseline B-vitamin status, or normal baseline Hcy status. They
also included analyses with cognitively impaired participants
combined with those with mild impairment and moderate AD and
trials that used insensitive cognitive outcomes such as the mini-
mental state examination. The few RCTs with positive results of
B-vitamin treatment not only used selective inclusion criteria (e.g.,
high baseline Hcy, participants with mild cognitive impairment or
mild AD), had large sample sizes and long-term interventions, butalso used sensitive domain-speciﬁc cognitive outcomemeasures for
episodic memory, processing speed, and executive function (de
Jager et al., 2012; Durga et al., 2007), for example, and the VITA-
COG trial used subtraction magnetic resonance imaging for
detecting rate of brain shrinkage as a marker of treatment efﬁcacy
(Smith et al., 2010).
The folate after coronary intervention trial (FACIT) showed
improved memory and processing speed performance in normal
older adults with elevated baseline Hcy after 3 years of intervention
with high-dose folic acid (800 mg per day). However, the dose was
not very high. The VITACOG Hcy-lowering trial showed a reduced
rate of brain shrinkage per year of up to 53% with high-dose treat-
mentwith3Bvitamins (B6, B9, andB12) for 2years. The reduced rate
of brain shrinkagewas dependent on the baselineHcy level,with the
most reduction observed in thosewith Hcy>13 mmol/L (Smith et al.,
2010). Furthermore, the reduction was shown to be in those areas
most relevant to AD pathology by voxel-based morphometry mea-
sures of structures including the hippocampus, parahippocampal,
fusiform, right angular, right supramarginal, lingual, and inferior
temporal gyri, and precuneus (Douaud et al., 2013).
The study also showed efﬁcacy for cognition in those who
started the study with Hcy levels >11.3 mmol/L. For participants on
treatment, decline was slowed in episodic memory, semantic
memory, executive function, and global cognition (de Jager et al.,
2012). There was a clinical effect for those who started the study
with Hcy >13 mmol/L, in that the Clinical Dementia Rating (CDR)
Scale overall scores improved signiﬁcantly, such that participants
had a 6-fold chance of reverting to a normal CDR score ¼ 0 on
treatment compared with placebo (de Jager et al., 2012). Fig. 1
depicts a simpliﬁed pathway of the effect of treatment as
described by Douaud et al. (2013). A Bayesian network analysis
suggested the following causal chain of events: treatment led to a
change in plasma concentrations of vitamin B12 and folate, with
only vitamin B12 appearing to play a role in modifying Hcy levels,
and lowering of Hcy levels caused a slowing in gray matter atrophy,
which, in turn, led to a modiﬁcation of the CDR (sum of boxes)
(model ﬁt, c2, p ¼ 0.64) (Douaud et al., 2013).
3. Critical thresholds of Hcy and brain atrophy
Critical to these treatment outcomes were the threshold levels
of Hcy and rate of atrophy on cognitive decline. In terms of Hcy, the
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baseline levels below these thresholds (in other words, those with
normal levels reﬂecting no B-vitamin deﬁciency) did not beneﬁt
from high-dose treatment >2 years. The extra B vitamins did not
improve their cognition at the group level. It was only the partici-
pants with elevated Hcy who showed a difference in their cognitive
scores that was dependent on the B-vitamin treatment. Those
without treatment declined signiﬁcantly more than those on
treatment.
3.1. Further analyses
To describe this critical level of brain shrinkage on cognitive
performance, novel data analysis comparing the measures of brain
shrinkage at the end of the VITACOG trial with certain cognitive
scores collected at a number of time points over the 2 years has
been performed. The rate of brain volume change was measured as
described previously (Smith et al., 2010), and the cognitive mea-
sures (Telephone Inventory for Cognitive StatusdModiﬁed [TICS-
M] and Hopkins Verbal Learning TestdDelayed Recall [HVLT-DR])
are described in de Jager et al. (2012) (supplementary appendix).
When these measures were analyzed by quartiles for rate of brain
shrinkage for all the trial participants with 2 magnetic resonance
imaging scans (n¼ 168), it was found that thosewho had the fastest
brain shrinkage showed the most cognitive decline (Fig. 2A and B).
Those whose brain shrinkage rate was lowest (in the upper 2
quartiles) showed no loss of cognitive performance over 2 years on
2 tests, the HVLT-DR and the TICS-M, tested multiple times during
the trial. For the HVLT-DR, those in the bottom 2 quartiles did show
decline, especially those in the bottom quartile where the atrophy
rate ranged from 1.27% to 3.32% per year. The cognitive decline was
most apparent after 12 months. Thereafter, the percentage correct
answers on the HVLT-DR dropped to as low as 35%, compared withFig. 2. Relation between quartiles of percentage rate of atrophy per year and (A)
Hopkins Verbal Learning Test, Delayed Recall (HVLT-DR) performance at 6 time points
and (B) Telephone Inventory for Cognitive Status, Modiﬁed (TICS-M) performance at 3
time points over 24 months.those in the upper 2 quartiles who scored about 70% correct an-
swers. Interestingly, those in the bottom quartile of atrophy started
the study with low cognitive performance (about 45% correct an-
swers) (Fig. 2A). Similarly, for the TICS-M, a global cognition test,
those in the upper quartile of brain shrinkage improved from 65% to
70% correct responses over the 2 years, whereas the bottom quartile
dropped from 60% correct to about 58%; so, the difference in per-
formance between the groups changed from 5% at baseline to 12%
after 2 years (Fig. 2B). Thus, one can conclude that there is a critical
level of brain shrinkage, which when reached, results in cognitive
decline, most marked in episodic memory performance. Thus, there
may be a certain window of opportunity to capture and reverse
cognitive decline. B-vitamin trials in those with more advanced AD
pathology may have been unsuccessful because of the severity of
brain atrophy already reached (Aisen et al., 2008); in the latter trial,
a signiﬁcant slowing of cognitive decline was found only for pa-
tients with mild AD. Thus, early intervention is indicated. Further
support for this concept comes from a clinical trial (Eastley et al.,
2000) showing that 66 patients with dementia and low B12 did
not improve their cognitive scores after 7 months of B-vitamin
treatment. However, 21 patients with early cognitive impairment
and low B12 did improve their verbal ﬂuency scores after 9 months
of treatment.
4. Dosages, dietary sources, and cautions with folic acid
fortiﬁcation
Although high doses of B vitamins have been used in RCTs (e.g.,
800 mg B12) and US recommendations for those >50 years are to
supplement with 250 mg per day, studies with B vitamins from the
diet indicate that between 6 and 10 mg B12 per day is sufﬁcient for
those not suffering from B12 deﬁciency (Vogiatzoglou et al., 2009).
Beyond this amount, a saturation point is reached, and absorption is
limited. This is still well above the amount of B12 in many sup-
plements where only 2 mg is included as the recommended daily
allowance in countries such as the United Kingdom. To obtain the
6e10 mg amount of vitamin B12 from the diet, foods rich in animal
protein are the best source. A study to determine the bioavailability
of B12 from animal foods including meat, ﬁsh, dairy products (milk,
cheese), and eggs concluded that the best bioavailable sources were
in milk and ﬁsh (Vogiatzoglou et al., 2009). Fish has not been found
to lose substantial amounts of B12 on cooking, whereas heating
milk reduces B12 by about 30% and similarly for cooked meat. Milk
contains 0.2e0.4 mg/100 g B12. The body absorbs up to 1.5e2 mg per
meal of B12 before the active transport mechanism is saturated.
Thus, half a liter of milk at 1 meal would supply 1e2 mg B12.
Low-dose vitamin B12 supplements (e.g., 0.2e2.0 mg per pill per
day) are ineffectively absorbed and show no effect on plasma levels.
However, supplements are a suitable alternative to dietary sources
for those groups or populations vulnerable to deﬁciency, including
older adults (because absorption from the gut is often poor),
pregnant or lactating mothers, vegetarians, and those in countries
with low animal-derived staple diets and those using folic acid
fortiﬁcation. Passive absorption of about 1% of supplemented B12
occurs and a dose of 500 mg per day would give an extra 5 mg to the
body even in those with no functional active mechanism. A study of
people on a macrobiotic diet revealed that 51% were B12 deﬁcient
and 30% had raised MMA levels (Miller et al., 1991).
4.1. Folic acid fortiﬁcation
Folic acid fortiﬁcation of foods was introduced as a measure to
prevent neural tube defects in the developing fetus and thus is
targeted at females of child-bearing age and pregnant women.
However, folic acid fortiﬁcation is not always beneﬁcial, especially
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suffering from pernicious anemia, which is quite common (Morris,
2012b). The folic acid will reduce Hcy levels but mask B12 deﬁ-
ciency, which if not treated will result in peripheral neuropathy,
tiredness, lack of energy, and permanent cognitive deﬁcits.
A vitamin B12 level <150 pmol/L is considered deﬁcient and a sign
of anemia. People with this condition are often treated with
intramuscular B12 injections (1000 mg) daily initially, followed by
monthly boosters that effectively reverse the condition and
improve memory performance. A combination of injections and
supplements has also been found to be highly effective (Butler et al.,
2006). In some cases, because of inﬂammatory factors and oxidative
stress associated with elevated Hcy, particular forms of vitamin B12
supplements such as glutathionyl-cobalamin may be more beneﬁ-
cial than others such as cyanocobalamin (Birch et al., 2009) in
combination with N-acetyl-L-cysteine.
Studies of the effects of high folic acid supplementation have
revealed deleterious effects on cognition (Smith, 2007). The Na-
tional Health and Nutrition Examination Survey study showed that
if both B12 and folic acid are at normal levels, there is no deﬁcit in
cognition. With normal B12 and high folate levels (>59 nmol/L),
cognition improved and reduced the odds of anemia by 0.5. How-
ever, low B12 (<148 pmol/L) with normal folate increased the odds
ratio for anemia to 2:1 and for cognitive impairment to 1.7:1. But the
most dramatic effects were seen with low B12 and high folate
where the odds ratio for anemia and cognitive impairment rose to
5:1 (Morris et al., 2007). Thus, food folic acid fortiﬁcation for those
with B12 deﬁciency is potentially harmful. A similar effect on
cognitive decline over 8 years for those with low B12 levels who
took folic acid supplements was shown in the Framingham study
(Morris et al., 2012). Folate occurs in many foods including dark
green, leafy vegetables, citrus fruits and juices, whole grains,
poultry, liver, and shellﬁsh. Thus, for vegetarians and older adults,
there should be no need for folic acid supplements.
5. Summary
Elevated Hcy is a risk factor for brain atrophy, cognitive decline,
and AD. Hcy can be lowered with B vitamins that are important
cofactors in the methylation cycle of Hcy. Together, these cofactors
play a role in DNA repair and integrity of the neural membranes;
thus, deﬁciencies will result in damage and brain atrophy.
Treatment with B vitamins can reduce the rate of brain
shrinkage in older adults, especially in those with elevated Hcy. The
treatment can also delay cognitive decline if taken long term (over 1
year) in those with high Hcy levels. Treatment is likely to be more
beneﬁcial in those whose brain shrinkage has not yet reached
critical levels and in those who do not yet have dementia.
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